{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+solution%2C+0.6%25",
    "query": {
      "intervention": "Saline solution, 0.6%"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 46,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline+solution%2C+0.6%25&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T21:06:32.499Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03718130",
      "title": "Combination HTNV and PUUV DNA Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hantaan Virus Disease, Puumala Virus"
      ],
      "interventions": [
        {
          "name": "Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 61,
      "start_date": "2019-07-10",
      "completion_date": "2022-10-07",
      "has_results": true,
      "last_update_posted_date": "2025-06-26",
      "last_synced_at": "2026-09-28T21:06:32.499Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03718130"
    },
    {
      "nct_id": "NCT04567329",
      "title": "Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "NOV03",
          "type": "DRUG"
        },
        {
          "name": "Saline Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 620,
      "start_date": "2020-11-18",
      "completion_date": "2021-08-30",
      "has_results": true,
      "last_update_posted_date": "2024-08-19",
      "last_synced_at": "2026-09-28T21:06:32.499Z",
      "location_count": 35,
      "location_summary": "Phoenix, Arizona • Garden Grove, California • Hemet, California + 29 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04567329"
    },
    {
      "nct_id": "NCT07220915",
      "title": "Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypogammaglobulinemia",
        "Autoimmune Conditions",
        "Rheumatic Conditions",
        "Infections"
      ],
      "interventions": [
        {
          "name": "Panzyga, 10% Intravenous Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2026-06-10",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-09-28T21:06:32.499Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220915"
    },
    {
      "nct_id": "NCT04763564",
      "title": "Efficacy of Liraglutide Therapy in Patients With IPAA",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pouchitis",
        "Irritable Pouch Syndrome"
      ],
      "interventions": [
        {
          "name": "Liraglutide Pen Injector",
          "type": "DRUG"
        },
        {
          "name": "Placebo Pen Injector",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2022-03-22",
      "completion_date": "2023-10-16",
      "has_results": true,
      "last_update_posted_date": "2024-07-23",
      "last_synced_at": "2026-09-28T21:06:32.499Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04763564"
    },
    {
      "nct_id": "NCT03038620",
      "title": "Impact of Liraglutide 3.0 on Body Fat Distribution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity, Visceral",
        "Cardiovascular Diseases",
        "Fat Disorder"
      ],
      "interventions": [
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 235,
      "start_date": "2017-01",
      "completion_date": "2020-10-13",
      "has_results": true,
      "last_update_posted_date": "2021-11-19",
      "last_synced_at": "2026-09-28T21:06:32.499Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03038620"
    },
    {
      "nct_id": "NCT06770491",
      "title": "A Phase 1 Study of Y-3 in US Healthy Volunteers.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety",
        "Tolerability",
        "Pharmacokinetic Study in Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Y-3 for injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurodawn Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-02-04",
      "completion_date": "2025-09-20",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-09-28T21:06:32.499Z",
      "location_count": 1,
      "location_summary": "Webster, Texas",
      "locations": [
        {
          "city": "Webster",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06770491"
    },
    {
      "nct_id": "NCT02967172",
      "title": "Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain, Postoperative",
        "Ankle Fractures"
      ],
      "interventions": [
        {
          "name": "Ropivacaine",
          "type": "DRUG"
        },
        {
          "name": "Epinephrine",
          "type": "DRUG"
        },
        {
          "name": "Morphine",
          "type": "DRUG"
        },
        {
          "name": "0.9% sodium chloride solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 100,
      "start_date": "2016-10",
      "completion_date": "2018-09-21",
      "has_results": true,
      "last_update_posted_date": "2023-12-15",
      "last_synced_at": "2026-09-28T21:06:32.499Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02967172"
    },
    {
      "nct_id": "NCT01727336",
      "title": "Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Dalantercept and axitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo and axitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2012-12",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2022-10-06",
      "last_synced_at": "2026-09-28T21:06:32.499Z",
      "location_count": 36,
      "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Irvine, California + 32 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01727336"
    },
    {
      "nct_id": "NCT03222492",
      "title": "Brentuximab Vedotin for Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis",
        "Scleroderma",
        "dcSSc"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 17,
      "start_date": "2017-09-20",
      "completion_date": "2023-04-10",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-09-28T21:06:32.499Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03222492"
    },
    {
      "nct_id": "NCT00294684",
      "title": "A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Biliary Atresia"
      ],
      "interventions": [
        {
          "name": "Corticosteroids",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "6 Months",
        "sex": "ALL",
        "summary": "Up to 6 Months"
      },
      "enrollment_count": 141,
      "start_date": "2005-11",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2019-10-22",
      "last_synced_at": "2026-09-28T21:06:32.499Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00294684"
    }
  ]
}